Navigation Links
Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
Date:9/13/2013

GERMANTOWN, Md., Sept. 13, 2013 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has agreed to a joint research and development initiative with Rentokil Initial PLC that may lead to a new generation of highly-effective and sustainable pest control product and solution.

Under the agreement, Intrexon will apply its biology and science expertise to assist Rentokil in the development of specific pest control products.  The companies will also consider exploring additional areas of commercial product research and development.  Additional terms of the agreement were not disclosed.

Intrexon's Chief Operating Officer, Krish Krishnan, said Rentokil's long history of developing innovative pest control products is invaluable to the collaboration.

"Intrexon and Rentokil share a common DNA: an unwavering commitment to producing ground-breaking solutions," Krishnan said. "The same biotechnologies that have served and benefitted our collaborations in Health and Food will be equally valuable towards advancing our goals in Intrexon's emerging Environment group."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with commercial-scale design and development of complex biological systems.  The UltraVector® platform enables unprecedented control over the quality, function, and performance of living cells for a wide variety of applications.  Intrexon calls it Better DNA™ and invites you to discover more at www.dna.com.

Trademarks
Intrexon, UltraVector and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:


Intrexon Corporation Contact:


Marie L. Rossi, Ph.D.

Manager, Technical Communications

Tel: +1 301-556-9944

mrossi@intrexon.com



 


'/>"/>
SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
3. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
4. Intrexon Organizes Around New Synthetic Biology Markets
5. Intrexon Announces Filing of Registration Statement For Proposed Initial Public Offering
6. Intrexon Prices Initial Public Offering
7. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
8. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
9. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
10. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
11. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):